Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
38.45B
Market cap38.45B
Price-Earnings ratio
70.99
Price-Earnings ratio70.99
Dividend yield
Dividend yield
Average volume
1.76M
Average volume1.76M
High today
$300.96
High today$300.96
Low today
$279.41
Low today$279.41
Open price
$295.51
Open price$295.51
Volume
2.50M
Volume2.50M
52 Week high
$495.55
52 Week high$495.55
52 Week low
$273.11
52 Week low$273.11

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $288.06. The company's market cap stands at 38.45B, with a P/E ratio of 70.99.

On 2026-07-13, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $279.41 and a high of $300.96. Shares are currently priced at $288.06, which is +3.1% above the low and -4.3% below the high.

Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 2.5M, against a daily average of 1.76M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $273.11.

ALNY News

TipRanks 6h
Alnylam price target raised to $485 from $470 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Alnylam (ALNY) to $485 from $470 and keeps a Buy rating on the shares after AstraZeneca (AZN) and Ionis Pharma...

Investing.com 8h
Truist cuts Alnylam stock price target to $410 on ATTR outlook - Investing.com

...

Truist cuts Alnylam stock price target to $410 on ATTR outlook - Investing.com
Simply Wall St 3d
Alnylam Pharmaceuticals Could Be 28% Undervalued Following Rival ATTR Trial Failure

Advertisement Why Alnylam Pharmaceuticals Stock Is Back in Focus Alnylam Pharmaceuticals (ALNY) moved sharply higher after a late stage trial for a competing...

Alnylam Pharmaceuticals Could Be 28% Undervalued Following Rival ATTR Trial Failure

Analyst ratings

73%

of 30 ratings
Buy
73.3%
Hold
26.7%
Sell
0%

More ALNY News

The Wall Street Journal 3d
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
Nasdaq 4d
Nasdaq 100 Movers: PEP, ALNY

In early trading on Thursday, shares of Alnylam Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 15.4...

Nasdaq 100 Movers: PEP, ALNY
TipRanks 4d
Alnylam price target raised to $468 from $420 at Raymond James

Raymond James raised the firm’s price target on Alnylam (ALNY) to $468 from $420 and keeps an Outperform rating on the shares. Ionis’ (IONS) failed Phase 3 ATTR...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.